Kornimate/medical-research-clean huggingface dataset:
validation of instruments used for assessment of dysphagia in patients with esophageal cancer

Conditions: Dysphagia, Esophageal; Esophageal Cancer

Summary: this study validates 3 well known dysphagia scores for dysphagia due to malignancies of the oesophagus and gastro-oesophageal junction and to the swedish language.

in the present study, our aim was to firstly, validate 3 commonly used scales for use in patients with dysphagia due to malignancy, and secondly, to validate them in the swedish language. the 3 scales were: the watson dysphagia scale, which was developed in studies on surgical treatment of reflux disease. it consists of questions about food with 9 different viscosity and solidity and the patient answer if they have problems with a specific food: never, sometimes or always when ingesting this. the scores are added and provides a range of 0-45 where 45 is the worst possible dysphagia. the ogilvie score is a 5-graded scale 0-4 where 4 is total inability to swallow. the goldschmid score is graded from 0-5 where 0 is inability to swallow and 5 is normal function. qol was measured with validated instruments originating from the european organization for research and treatment of cancer (eortc), which has a generic instrument that measures global qol in patients with cancer (qlq-c30) and a more symptom-specific instrument that is developed for cancer in the oesophagus and stomach (qlq-og25). these are well known, validated instruments that also have normal reference values for the healthy population. the symptom specific instrument qlq-og25 includes a dysphagia module consisting of 3 questions which is validated to malignant disease and food intake with the help of expert groups and deep interviews with patients.

Eligibility criteria:
inclusion criteria: * cancer in the gastro-esophageal junction or in the esophagus * dysphagia * ability to fill in the questionnaires * written acceptance of the informed consent exclusion criteria: * not for-filling inclusion criteria * no consent

Keywords: cancer of the gastro-esophageal junction watson score ogilvie score goldschmid score validation quality of life
molecular subtyping of triple-negative breast cancer and african ancestry-related immunogenicity

Conditions: Triple Negative Breast Cancer

Summary: triple-negative breast cancer (tnbc) is a heterogeneous disease that is associated with a younger age of onset, worse stage matched-outcomes, and women of african ancestry in north america. a higher incidence of tnbc is also seen in west africa, despite unique environmental, socioeconomic and modifiable risk factors. transcriptome analysis of tnbc has delineated four distinct subgroups with therapeutic and prognostic significance. with further characterization, important regional differences have emerged between populations of african vs. european ancestry. these differences may have significant implications for the efficacy of novel tnbc-targeted therapy and need to be further evaluated. transcriptional data on tnbc in sub-saharan african also offers the opportunity to evaluate the relationship between breast cancer phenotype and ancestry-linked differences in the tumor-immune microenvironment.

this study seeks to characterize the mrna profile of tnbc in nigeria and compare to a reference population in nova scotia. insight into the unique tumor-immune profile of tnbc in nigeria and the link between the west african-linked duffy-antigen receptor for chemokines (darc) and tnbc subtype will be explored for the first time. fresh frozen tnbc tissue from the african research group for oncology (argo) and dalhousie/nsha breast cancer biobanks' will be processing and analyzed by the genomics core facility at dalhousie university. clinical data is prospectively collected with specimen acquisition in the argo biobank. for the dalhousie /nsha biobank, clinical data will be retrospectively gathered from the medical record and migrated to an electronic database for prospective collection during the course of the study. both cohorts of specimens will be run through dna and whole transcriptome (mrna) sequencing on the tso500 platform (illumina ulc.). the tumor-immune microenvironment will be compared between cohorts and by mrna cluster using the transcriptional signatures for 22 leukocyte populations and immune-regulating proteins ctla-4 and pd-l1. finally, tumor expression of darc will be generated from the transcriptome data that will allow for an assessment of the relationship between darc expression, tnbc mrna clusters, and sociodemographic variables (i.e. race/ancestry, gender). whole transcriptome data from the cancer genome atlas will be pulled as the third cohort, including 55 tnbc specimens from african americans.

Eligibility criteria:
inclusion criteria: * diagnosed with triple-negative breast cancer exclusion criteria: * no diagnosis of triple-negative breast cancer
cardiopulmonary resuscitation by children

Conditions: Cardiopulmonary Arrest With Successful Resuscitation

Summary: children's education students are able to identify a possible emergency and in their case act appropriately. the authors think that the propsed training will improve the knowledge, change the attitude and improve their practical skills, and also retain the information over time.

cardiopulmonary resuscitation (cpr) formation in children and teachers is a current and high impact topic in public health: with an appropriate training anyone can save life (böttiger, 2015). primary school students are willing to learn cpr and they are also carriers of knowledge among their surroundings like family or friends (martínez, 2015). the authors propose a clinical trial to evaluate the knowledge, attitudes and skills in primary education students of various schools, before and after a cpr formation. the schools will be previously randomized in intervention group and control group. once the intervention has been completed and the results obtained, training equal to the intervention will be offered to the control schools. in the bibliographic search no validated questionnaires in cpr learning among primary education students has been found.

Eligibility criteria:
inclusion criteria: * spanish primary education students attending the 5th level. * informed consent signed by parents or tutors exclusion criteria: • spanish primary school children with learning disabilities.

Keywords: cardiopulmonary resuscitation teaching material primary education
identifying vitamin d deficiency in very low birth weight infant (vlbw) infants part 2

Conditions: Infant, Very Low Birth Weight; Calcium Deficiency; Vitamin D Deficiency

Summary: this study is to determine the amount of vitamin d required for a very low birth weight infant to reach vitamin d sufficiency and achieve optimal calcium health and bone growth.


Eligibility criteria:
inclusion criteria: * any infant born at the medical university of south carolina \<34 weeks gestation * less that 1500g at birth * aga * must be african american or caucasian * each infant born of twin and triplet pregnancies will be eligible exclusion criteria: * infants with major congenital anomalies or with hemolytic disease requiring exchange transfusion * infants born small for-gestational-age (sga) or large for-gestational-age (lga) * maternal uncontrolled thyroid disease * maternal parathyroid disease * infants of races other than african american or caucasian

Keywords: vitamin d preterm infants calcium bone parathyroid hormone
support annual strain update, safety and immunogenicity of an inactivated, adjuvanted influenza vaccine, formulation 2007-2008, when administered to subjects 18-64 years affected by chronic diseases.

Conditions: Influenza Disease

Summary: this phase ii, open label, is designed as a seasonal study to support annual strain update evaluating the safety, clinical tolerability and immunogenicity of the 2007-2008 formulation of novartis vaccines' adjuvanted, subunit influenza vaccine in adults with underlying chronic diseases


Eligibility criteria:
inclusion criteria: * 18 to 64 years of age adult volunteers, mentally competent, willing and able to give written informed consent prior to study entry, suffering from at least one of these chronic diseases: hypertension, heart disease, chronic obstructive pulmonary disease (copd) or asthma, hepatic or renal insufficiency, arteriosclerotic disease or insulin dependent diabetes mellitus exclusion criteria: * hypersensitivity to ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulphate or any other component of the vaccine; * history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine; * known or suspected impairment/ alteration of immune function; * having received within the past 12 months more than one injection of influenza vaccine * any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives

Keywords: influenza influenza vaccine adjuvanted influenza vaccine subunit influenza vaccine surface antigen
gulf war 1 veteran healthcare satisfaction

Conditions: Persian Gulf War Syndrome in Veteran

Summary: the purpose of this study is to investigate gulf war 1 veteran (gw1v) patient perceptions of, and satisfaction with, their va primary care treatment, and physician effectiveness in delivering improved point of service, in the primary care clinics at the veterans administration (va) salt lake city health care system.

veterans of the 1990-1991 gulf war1 (gw1) conflict are still experiencing a host of adverse health conditions at the present time. many gw1 veterans are still unhappy with their health care at the va, and other stakeholders are critical of how the va has dealt with gw1 veterans' issues. for these reasons, the gulf war veterans' illness task force (gwvi-tf) was set up to find ways to improve the situation. the present survey study addresses one of gwvi-tf's missions, that is, to identify gaps in va services, and to discover opportunities to better serve gw1v. caring for gw1v is a top priority for va health care providers, which is all the more pressing for the following reasons: 1. medical science of gulf war illness and environmental exposures is still at its infancy, 2. most providers have not received any focused education about how to take care of gw1v and the unique medical problems these veterans face, 3. a lack of provider knowledge that gw1v may receive may lead to decreased satisfaction on the part of gw1v and may result in gw1v perceived health service quality that is compromised. in this pilot study, we focus on #2 and #3, to determine how we may understand veterans' perceptions of their medical treatment to ultimately improve gw1v medical health outcomes.

Eligibility criteria:
inclusion criteria: * a gulf war veteran who served during the persian gulf war (gw1) of 1990-1991 * currently treated by a primary care physician at the vaslchcs exclusion criteria: * cannot read and write english

Keywords: patient satisfaction gulf war 1 veteran desert storm veteran
a study to evaluate the safety and efficacy of omarigliptin (mk-3102) compared with glimepiride in participants with type 2 diabetes mellitus for whom metformin is inappropriate (mk-3102-027)

Conditions: Type 2 Diabetes Mellitus

Summary: this trial will assess the safety and efficacy of omarigliptin (mk-3102) compared with the sulfonylurea, glimepiride, in type 2 diabetes mellitus participants who are metformin intolerant or who have a contraindication to the use of metformin. the primary hypothesis is that after 54 weeks, the mean change from baseline in hemoglobin a1c (a1c) in participants treated with omarigliptin is non-inferior compared with that in participants treated with glimepiride.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes mellitus * have intolerability to metformin ≥1000 mg/day or have a contraindication to the use of metformin * females of reproductive potential agree to remain abstinent or use or have their partner use 2 acceptable methods of birth control exclusion criteria: * history of type 1 diabetes mellitus or a history of ketoacidosis or assessed by the investigator as possibly having type 1 diabetes * has been treated with: 1. a thiazolidinedione (tzd) within 4 months of study participation, or 2. a glucagon-like peptide-1 (glp-1) receptor mimetic or agonist (such as exenatide or liraglutide) within 6 months of study participation, or 3. insulin within 12 weeks prior to study participation, or 4. dual antihyperglycemic agent (aha) therapy within 12 weeks of study participation (4 months if a component of the dual aha therapy was a tzd) 5. omarigliptin (mk-3102) at any time prior to study participation * on a weight loss program and is not in the maintenance phase; has started a weight loss medication in the past 6 months; or has undergone bariatric surgery within 12 months prior to study participation * medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis b or c, primary biliary cirrhosis, or symptomatic gallbladder disease * human immunodeficiency virus (hiv) * new or worsening coronary heart disease, congestive heart failure, myocardial infarction, unstable angina, coronary artery intervention, stroke or transient ischemic neurological disorder within the past 3 months * history of malignancy ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer * clinically important hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) * pregnant or breast-feeding, or is expecting to conceive or donate eggs during the trial, including 21 days following the last dose of study drug
early parenting intervention comparison

Conditions: Behavior Problems, Child

Summary: the purpose of this study is to compare the effectiveness of two parenting programs in a mental health clinic serving young children with behavior problems.


Eligibility criteria:
inclusion criteria: * child 2 to 5 years old * parent reports reason for referral is child behavior problems * parent is a biological or adoptive parent, or legal guardian of child exclusion criteria: * parent is psychotic or actively abusing substances * child is autistic or severely developmentally delayed

Keywords: preschool children behavior problems child between 2 and 5 years old
reverse shoulder replacement: formal vs. home physiotherapy

Conditions: Shoulder Arthropathy Associated With Other Conditions

Summary: the purpose of this study is to compare range of motion between a structured home exercise program to supervised physiotherapy post-operatively after reverse total shoulder replacement is performed for rotator cuff tear arthropathy/massive cuff tear through a single-center, assessor-blinded, randomized clinical trial.

all patients who are evaluated by one of three shoulder/elbow fellowship-trained surgeons at washington university department of orthopedic surgery and who meet the inclusion criteria will be offered enrollment in the study. following consent the participant will be asked to undergo an exam of the shoulder and complete questionnaires related to shoulder pain and function. demographic information, health history related to the affected shoulder, and co-morbidity data will also be collected preoperatively. patients will be randomized to either a simple, standardized home exercise program or a supervised physiotherapy program administered by a physical therapist after undergoing a standardized operative protocol for reverse total shoulder arthroplasty. post-operative range of motion will be measured in a blinded fashion at 6 weeks, 3 months, 6 months, and 12 months. a blinded observer will simultaneously measure validated functional outcomes scores including the western ontario osteoarthritis score, american shoulder and elbow surgeons score and visual analogue score for pain pre-operatively and at 6 weeks, 3 months, 6 months, and 12 months post-operatively.

Eligibility criteria:
inclusion criteria: 1. primary rtsa for the diagnosis of rotator cuff tear arthropathy (rcta) or irreparable rotator cuff tear. 2. a pre-operative plan for rtsa 3. age \>60 exclusion criteria: 1. active infection 2. incompetent deltoid muscle 3. unwillingness or inability to participate in a home exercise program 4. medically unfit for operative intervention 5. revision rtsa 6. rtsa for glenohumeral osteoarthritis or proximal humerus fracture 7. unwillingness to participate in the study 8. inability to read or comprehend written instructions

Keywords: reverse total shoulder arthroplasty post operative physical therapy
sms-guided training after acute stroke or transient ischemic attack - a randomized controlled trial

Conditions: Acute Stroke; TIA (Transient Ischemic Attack)

Summary: eighty community-living individuals in uppsala municipality will be included. intervention: outdoor walking exercise program and one strength exercise. methods: clinical assessments, questionnaires and medical records. assessment of motor function, cognition, level of physical activity, food intake and perceived stress are performed at screening as baseline measurements. walking capacity, mobility, handgrip strength, body composition and cardiovascular risk markers will be assessed at baseline and after 12 week of training. at one year after training health-related quality of life, another cardiovascular incidence and mortality will be documented.

eighty community-living individuals in uppsala municipality will be included in a randomized controlled trial with two arms. intervention: participants will perform an outdoor walking exercise program together with one strength exercise for 12 weeks. the intensity and frequency of the training will progressively increase. participants are supposed to walk and perform strength training 5-7 days/week. methods: clinical assessments, questionnaires and medical records used for documentation of age, sex, comorbidity, blood pressure, medications and previous education. assessment of motor function, cognition, level of physical activity, food intake and perceived stress are performed at screening as baseline measurements. walking capacity (primary outcome measure), mobility, handgrip strength, body composition and cardiovascular risk markers will be assessed at baseline and after 12 week of training. at one year after training health-related quality of life, another cardiovascular incidence and mortality will be evaluated. power analysis is performed. the investigators will analyze the data using an intention-to -treat analysis. participants should have participated in at least 50% of the training sessions

Eligibility criteria:
inclusion criteria: 1. verified ischemic cerebral infarction or intracerebral hemorrhage. 2. sufficient walking capacity and motor function 3. able to communicate in swedish 4. signed consent exclusion criteria: one or more of the following: 1. subarachnoid bleeding 2. insufficient cognition and impaired ability to understand instructions 3. medical problems that make it unsuitable to participate 4. pacemaker (body composition measurements)

Keywords: mobility exercise walking capacity fat mass muscles
a study in patients with fabry disease who are on chronic hemodialysis therapy for treatment of end-stage renal insufficiency.

Conditions: Fabry Disease

Summary: people with fabry disease have an alteration in their genetic material (dna) which causes a deficiency of the a-galactosidase a enzyme. fabrazyme is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." these glycolipids are normally present within the body in most cells. in fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase a is not present, or is present in small quantities. the build up of glycolipid (globotriaosylceramide or gl-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to fabry disease. this study is designed to verify that no loss of fabrazyme occurs during simultaneous fabrazyme infusion and hemodialysis in patients currently receiving fabrazyme at a dose of 1.0 mg/kg every 2 weeks.


Eligibility criteria:
inclusion criteria: * patient must provide signed, written informed consent prior to any study-related procedures being performed. * patient is between 18 and 65 years of age, inclusive. * patient has documented fabry disease. * patient has received bi-weekly 1 mg/kg infusions of fabrazyme for at least 6 months prior to enrollment into the study. * patient has not experienced moderate or severe infusion-associated reactions (iars) from fabrazyme infusions, which were also associated with a rate reduction, within 3 months prior to enrollment into the study. * patient has been receiving chronic hemodialysis for treatment of end-stage renal insufficiency for at least 3 months prior to enrollment into the study. * patient has good vascular access for hemodialysis. * patient has not and will not have any other (investigational) drug(s) infused during their hemodialysis, and is expected to have a stable concomitant medication regimen at all pk assessments. exclusion criteria: * patient's hemoglobin is \< 9 g/100 ml at screening/baseline. * patient has a clinically significant organic disease or an unstable condition that, in the opinion of the investigator, would preclude participation in the study. * patient has a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance. * patient has participated in a study employing an investigational drug within 30 days prior to the start of their participation in this study. * patient is unwilling to comply with the requirements of the protocol.

Keywords: agalsidase beta alpha galactosidase a agal rh agal fabry gl3 fabrazyme dialysis hemodialysis